Literature DB >> 10929929

Humoral immune response to influenza vaccination in patients from high risk groups.

L B Brydak1, M Machala.   

Abstract

Influenza is one of the most common respiratory diseases. Infections caused by this virus may be very serious and can lead to severe complications. So far, the most effective method of protection against influenza is annual vaccination. The Advisory Committee on Immunisation Practices recommends vaccination against influenza for some groups of people. Unfortunately, in spite of these clear indications, a large number of patients are not vaccinated. This article reviews the current scientific literature on immunological response to influenza vaccination in patients who are at especially high risk for serious post-influenza complications and for whom immunisation against this virus is strongly recommended. Results of studies carried out in Poland and other countries in elderly people, in patients with pulmonary diseases, renal diseases, diabetes mellitus, cancer and haemophilia, and in those with HIV infection are presented. In this review, we focus on the immune response to haemagglutinin. There are some discrepancies between the results of studies carried out by different authors in high risk groups of patients. Some investigations indicated poorer humoral response to influenza vaccine in these groups, while others showed responses comparable to those in healthy individuals. These differences may be explained by differences in types and stages of the chronic diseases, in the treatment and composition of influenza vaccines, and also patients' ages, vaccination history and prevaccination antibody titres. Influenza vaccines are well tolerated in high risk patients, and all adverse reactions are generally mild and similar to those observed in healthy people. Although, in some cases, immunological responses to influenza vaccination measured in the whole study group were poor, there were some individual patients who, after vaccination, developed antihaemaglutinin antibody titres which are considered to give protection against the infection or contribute to a milder course of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929929     DOI: 10.2165/00003495-200060010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  87 in total

1.  Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland.

Authors:  L B Brydak; R Rokicka-Milewska; T Jackowska; H Rudnicka; H Regnery; N Cox
Journal:  Leuk Lymphoma       Date:  1997-06

2.  Socioeconomics of influenza and influenza vaccination in Europe.

Authors:  K G Nicholson
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

3.  Influenza: a shot or not?

Authors:  C B Hall
Journal:  Pediatrics       Date:  1987-04       Impact factor: 7.124

4.  Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients.

Authors:  A Bucalossi; G Marotta; P Galieni; C Bigazzi; P E Valenzin; E Dispensa
Journal:  Acta Haematol       Date:  1995       Impact factor: 2.195

5.  Current status of vaccines and immune globulins for children with renal disease.

Authors:  R W Steele
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

6.  Influence of some immune factors on the IL-6 and soluble IL-2 receptors in haemodialysed patients.

Authors:  M Kozioł-Montewka; A Ksiazek; M Majdan; D Spasiewicz; L Brydak; L Janicka; S Toś-Luty; J Sitkowska; C Skórska; J Latoszyńska; E Przylepa
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

7.  Time to peak serum antibody response to influenza vaccine in the elderly.

Authors:  P A Gross; C Russo; M Teplitzky; S Dran; P Cataruozolo; G Munk
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

8.  Antibody response to tetravalent influenza subunit vaccine in patients infected with human immunodeficiency virus type 1.

Authors:  M M Schneider; M J Sprenger; I M Hoepelman; Y van der Graaf; J C Borleffs
Journal:  Int J Antimicrob Agents       Date:  1996-04       Impact factor: 5.283

9.  Influenza immunization of children with neoplastic diseases.

Authors:  P G Steinherz; A E Brown; P A Gross; D Braun; F Ghavimi; N Wollner; G Rosen; D Armstrong; D R Miller
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

10.  Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial.

Authors:  T M Govaert; G J Dinant; K Aretz; N Masurel; M J Sprenger; J A Knottnerus
Journal:  BMJ       Date:  1993-10-16
View more
  22 in total

1.  Immune response to influenza vaccination in an elderly population.

Authors:  Lidia B Brydak; Magdalena Machała; Jolanta Myśliwska; Andrzej Myśliwski; Piotr Trzonkowski
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

2.  Influenza update: a review of currently available vaccines.

Authors:  Lisa R Clayville
Journal:  P T       Date:  2011-10

3.  Hemagglutination inhibiting antibody persistence 1 year after influenza vaccination in Korean children and adolescents.

Authors:  Eun Kyeong Kang; Byung Wook Eun; Nam Hee Kim; Yun Kyung Kim; Jung Sub Lim; Dong Ho Kim
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

4.  Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus.

Authors:  Seo Rin Kim; Soo Bong Lee; Il Young Kim; Dong Won Lee; Harin Rhee; Eun Young Seong; Sang Heon Song; Ihm Soo Kwak
Journal:  Clin Exp Nephrol       Date:  2011-11-25       Impact factor: 2.801

5.  Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.

Authors:  Manpreet K Chadha; Marwan Fakih; Josephia Muindi; Lili Tian; Terry Mashtare; Candace S Johnson; Donald Trump
Journal:  Prostate       Date:  2010-09-01       Impact factor: 4.104

6.  Turkey versus guinea pig red blood cells: hemagglutination differences alter hemagglutination inhibition responses against influenza A/H1N1.

Authors:  Inna G Ovsyannikova; Sarah J White; Randy A Albrecht; Adolfo García-Sastre; Gregory A Poland
Journal:  Viral Immunol       Date:  2014-04-30       Impact factor: 2.257

Review 7.  Influenza vaccinations: who needs them and when?

Authors:  Eelko Hak; Arno W Hoes; Theo J M Verheij
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Nicholas V Mendez; Ana Marie Landin; John G Ryan; Bonnie B Blomberg
Journal:  Vaccine       Date:  2013-05-25       Impact factor: 3.641

9.  Antibody response to influenza vaccination in splenectomized patients in Poland.

Authors:  Lidia B Brydak; Magdalena Machała; Paweł Łaguna; Roma Rokicka-Milewska
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

10.  Immunogenicity of Influenza Vaccination in Patients With Cancer.

Authors:  Saiama N Waqar; Leigh Boehmer; Daniel Morgensztern; Andrea Wang-Gillam; Steven Sorscher; Steven Lawrence; Feng Gao; Kalin Guebert; Kristina Williams; Ramaswamy Govindan
Journal:  Am J Clin Oncol       Date:  2018-03       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.